← Back to Search

Other

TransCon CNP for Achondroplasia (AttaCH Trial)

Phase 2 & 3

Waitlist Available

Research Sponsored by Ascendis Pharma Growth Disorders A/S

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through trial completion, an average of 10 years

Awards & highlights

AttaCH Trial Summary

This trial will study the effects of TransCon CNP on people aged 2-18 with achondroplasia. Treatment will continue until femur and tibial epiphyseal closure is confirmed, with visits every 12-14 weeks.

Who is the study for?

This trial is for children and adolescents with achondroplasia who have already been part of a previous TransCon CNP study. They must be able to receive weekly injections, have parental consent, and meet safety criteria from the prior trial. Those unable to complete the study or at risk due to other conditions are excluded.Check my eligibility

What is being tested?

The long-term safety, tolerability, and effectiveness of TransCon CNP given once a week are being tested in young patients with achondroplasia until they reach skeletal maturity (16 years for females, 18 years for males), confirmed by radiographic imaging.See study design

What are the potential side effects?

Specific side effects aren't listed here but may include reactions related to subcutaneous injection or hypersensitivity to ingredients like trehalose, tris[hydroxymethyl]aminomethane, succinate, and methoxy polyethylene glycol.

AttaCH Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through trial completion, an average of 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through trial completion, an average of 10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and through trial completion, an average of 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Height Z-scores

Safety and Tolerability

Secondary outcome measures

Annualized Growth Velocity

AttaCH Trial Design

1Treatment groups

Experimental Treatment

Group I: TransCon CNP 100 mcgExperimental Treatment1 Intervention

TransCon CNP 100 mcg delivered once weekly by subcutaneous injection

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Ascendis Pharma Growth Disorders A/SLead Sponsor

2 Previous Clinical Trials

156 Total Patients Enrolled

2 Trials studying Achondroplasia

156 Patients Enrolled for Achondroplasia

Silas Gylvin, MDStudy DirectorAscendis Pharma

1 Previous Clinical Trials

57 Total Patients Enrolled

1 Trials studying Achondroplasia

57 Patients Enrolled for Achondroplasia

Adebola Giwa, MDStudy DirectorAscendis Pharma

2 Previous Clinical Trials

317 Total Patients Enrolled

2 Trials studying Achondroplasia

317 Patients Enrolled for Achondroplasia

Media Library

TransCon CNP (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05929807 — Phase 2 & 3

Achondroplasia Research Study Groups: TransCon CNP 100 mcg

Achondroplasia Clinical Trial 2023: TransCon CNP Highlights & Side Effects. Trial Name: NCT05929807 — Phase 2 & 3

TransCon CNP (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05929807 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is eligible to take part in this research endeavor?

"This study is looking to recruit 140 people with achondroplasia, between the ages of 3 and 15. If accepted in this trial, they will have the opportunity to receive treatment."

Answered by AI

Does the age qualification for this research begin at twenty-five?

"This clinical trial specifically targets children aged 3 to 15. Those below 18 years old have 11 trials available while those above 65 can apply for a total of 3 studies."

Answered by AI

In what geographic areas is the clinical research being conducted?

"As of now, the trial is seeking enrolment from 7 sites including Buffalo, Little Rock and Madison. Therefore, it is advisable to select a nearby clinic in order to reduce travel commitments for participants."

Answered by AI

Are there any vacancies left in this trial for potential participants?

"Data published on clinicaltrials.gov states that this particular trial, which was first made available to the public on June 21st 2023 and last modified August 17th 2023, is no longer actively recruiting patients. Nonetheless, 12 alternative medical trials are still searching for eligible participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

2023. "A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05929807.

All > Achondroplasia